{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:32:31Z","timestamp":1787031151622,"version":"build-2736575974"},"reference-count":110,"publisher":"Baishideng Publishing Group Inc.","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Diabetes"],"DOI":"10.4239\/wjd.v13.i10.835","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T23:01:17Z","timestamp":1665702077000},"page":"835-850","source":"Crossref","is-referenced-by-count":23,"title":["New therapeutic approaches for type 1 diabetes: Disease-modifying therapies"],"prefix":"10.4239","volume":"13","author":[{"given":"Geza","family":"Nagy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tekla Evelin","family":"Szekely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniko","family":"Somogyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdolna","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2022,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.6285"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12099"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12033"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-2929-6"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00351"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3402"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-233585"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/db10-1643"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-S067"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v6.i5.526"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80195-8"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1419"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-016-2499-2"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5448.2008.00464.x"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3067-x"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31320-5"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0465"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1952"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1035-y"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(86)91943-4"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/BF00403182"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60895-7"},{"key":"B23","unstructured":"Provention Bio Inc. Provention Bio Receives Complete Response Letter (CRL) to Biologics License Application (BLA) for Teplizumab for the Delay of Clinical Type 1 Diabetes (T1D) in At-risk Individuals. Cited 10 May 2022. Available from: https:\/\/investors.proventionbio.com\/2021-07-06-Provention-Bio-Receives-Complete-Response-Letter-CRL-to-Biologics-License-Application-BLA-for-Teplizumab-for-the-Delay-of-Clinical-Type-1-Diabetes-T1D-in-At-risk-Individuals"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2011.03.006"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904452"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0626"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/db11-0674"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100539"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14723"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-018-0032-1"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2013.01.016"},{"key":"B32","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Rituximab and Abatacept for Prevention or Reversal of Type 1 Diabetes (TN25). [accessed 05 August 2022]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03929601 ClinicalTrials.gov Identifier: NCT03929601"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60886-6"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0604"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.07.086"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0744-z"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0047"},{"key":"B38","unstructured":"Greenbaum C. Early Markers of Disease and Response to Therapy. [accessed 05 August 2022]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04118153 ClinicalTrials.gov Identifier: NCT04118153"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199457110-00001"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.1.123"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001830"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.6.1763"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012864"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.04.007"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2753-4"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1207"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0345"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60931-8"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0236"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902226"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4786-9"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201545708"},{"key":"B53","unstructured":"Provention Bio Inc. At-Risk for Type 1 Diabetes Extension Study. [accessed 05 August 2022]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04270942 ClinicalTrials.gov Identifier: NCT04270942"},{"key":"B54","unstructured":"Provention Bio Inc. Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab (PROTECT). [accessed 05 August 2022]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03875729 ClinicalTrials.gov Identifier: NCT03875729"},{"key":"B55","unstructured":"Provention Bio Inc. Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab. [accessed 05 August 2022]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04598893 ClinicalTrials.gov Identifier: NCT04598893"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043980"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05317-y"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13842"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0327"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12361"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1575"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-204875"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-101241"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70065-2"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3917-4"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78492"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0823"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0494"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.2337\/db19-0057"},{"key":"B70","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases.   Low Dose Antithymocyte Globulin (ATG) to Delay or Prevent Progression to Stage 3 T1D (TN28). [accessed 05 August 2022]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04291703 ClinicalTrials.gov Identifier: NCT04291703"},{"key":"B71","unstructured":"Mathieu C.   MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D). [accessed 05 August 2022]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04509791 ClinicalTrials.gov Identifier: NCT04509791"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3509-8"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.04.005"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3212"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1218"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1021\/pr400527q"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00019-X"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2022.101682"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2011.01509.x"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3727\/096368915X689622"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1089\/ten.TEA.2008.0579"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3267"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102406"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0538"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.05.045"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00016"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2000.7389"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i20.3016"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2010.02.005"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.574119"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/med.21322"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010088"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04178.x"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902007"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0307140"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2013.09.006"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1186\/scrt216"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2018.10.005"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej12-0343"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2015.03.608"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-013-0266-1"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00993"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000368"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0171"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2021.09.015"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-021-02417-3"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0656"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-02941-w"},{"key":"B109","unstructured":"Vinmec Research Institute of Stem Cell and Gene Technology.   Evaluate Safety of Adipose Derived Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Treatment. [accessed 05 August 2022]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05308836 Cited: ClinicalTrials.gov Identifier: NCT05308836"},{"key":"B110","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases.   Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells. [accessed 05 August 2022]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04061746 ClinicalTrials.gov Identifier: NCT04061746"}],"container-title":["World Journal of Diabetes"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-9358\/full\/v13\/i10\/835.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T23:01:34Z","timestamp":1665702094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-9358\/full\/v13\/i10\/835.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,15]]},"references-count":110,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.4239\/wjd.v13.i10.835","relation":{},"ISSN":["1948-9358"],"issn-type":[{"value":"1948-9358","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,15]]}}}